182 related articles for article (PubMed ID: 38172306)
1. Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation.
Li XX; Chen ZD; Sun XJ; Yang YQ; Jin H; Liu NF
Acta Pharmacol Sin; 2024 Apr; 45(4):751-764. PubMed ID: 38172306
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3/caspase-1/GSDMD pathway in pancreatic β cells: in vitro and in vivo studies.
Liu P; Zhang Z; Wang J; Zhang X; Yu X; Li Y
Bioengineered; 2021 Dec; 12(2):9356-9366. PubMed ID: 34823419
[TBL] [Abstract][Full Text] [Related]
3. Favorable effect of rivaroxaban against vascular dysfunction in diabetic mice by inhibiting NLRP3 inflammasome activation.
Li Q; Yang XT; Wei W; Hu XP; Li XX; Xu M
J Cell Physiol; 2022 Aug; 237(8):3369-3380. PubMed ID: 35675485
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome.
Chen A; Lan Z; Li L; Xie L; Liu X; Yang X; Wang S; Liang Q; Dong Q; Feng L; Li Y; Ye Y; Fu M; Lu L; Yan J
Cardiovasc Res; 2023 Oct; 119(13):2368-2381. PubMed ID: 37523743
[TBL] [Abstract][Full Text] [Related]
5. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
6. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of acarbose against vascular endothelial dysfunction through inhibiting Nox4/NLRP3 inflammasome pathway in diabetic rats.
Li XX; Ling SK; Hu MY; Ma Y; Li Y; Huang PL
Free Radic Biol Med; 2019 Dec; 145():175-186. PubMed ID: 31541678
[TBL] [Abstract][Full Text] [Related]
8. Salidroside alleviates diabetic neuropathic pain through regulation of the AMPK-NLRP3 inflammasome axis.
Zheng T; Wang Q; Bian F; Zhao Y; Ma W; Zhang Y; Lu W; Lei P; Zhang L; Hao X; Chen L
Toxicol Appl Pharmacol; 2021 Apr; 416():115468. PubMed ID: 33639149
[TBL] [Abstract][Full Text] [Related]
9. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y; Bajaj M; Yang HC; Ye Y
Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
[TBL] [Abstract][Full Text] [Related]
10. Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
Gordon M; Meagher P; Connelly KA
Can J Diabetes; 2021 Aug; 45(6):553-556. PubMed ID: 33388277
[TBL] [Abstract][Full Text] [Related]
11. Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice.
Yu Y; Chen D; Zhao Y; Zhu J; Dong X
Int J Immunopathol Pharmacol; 2021; 35():20587384211036819. PubMed ID: 34399601
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db/db mice.
Gong Q; Zhang R; Wei F; Fang J; Zhang J; Sun J; Sun Q; Wang H
Biomed Pharmacother; 2022 Aug; 152():113222. PubMed ID: 35671581
[TBL] [Abstract][Full Text] [Related]
13. Contribution of redox-dependent activation of endothelial Nlrp3 inflammasomes to hyperglycemia-induced endothelial dysfunction.
Chen Y; Wang L; Pitzer AL; Li X; Li PL; Zhang Y
J Mol Med (Berl); 2016 Dec; 94(12):1335-1347. PubMed ID: 27783111
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1-Adiponectin Axis.
Ye T; Zhang J; Wu D; Shi J; Kuang Z; Ma Y; Xu Q; Chen B; Kan C; Sun X; Han F
Front Endocrinol (Lausanne); 2022; 13():907984. PubMed ID: 35784553
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Byrne NJ; Matsumura N; Maayah ZH; Ferdaoussi M; Takahara S; Darwesh AM; Levasseur JL; Jahng JWS; Vos D; Parajuli N; El-Kadi AOS; Braam B; Young ME; Verma S; Light PE; Sweeney G; Seubert JM; Dyck JRB
Circ Heart Fail; 2020 Jan; 13(1):e006277. PubMed ID: 31957470
[TBL] [Abstract][Full Text] [Related]
17. Paeoniflorin ameliorates diabetic liver injury by targeting the TXNIP-mediated NLRP3 inflammasome in db/db mice.
Wang A; Gong Y; Pei Z; Jiang L; Xia L; Wu Y
Int Immunopharmacol; 2022 Aug; 109():108792. PubMed ID: 35483236
[TBL] [Abstract][Full Text] [Related]
18. Gastrodin Alleviates Cognitive Dysfunction and Depressive-Like Behaviors by Inhibiting ER Stress and NLRP3 Inflammasome Activation in db/db Mice.
Ye T; Meng X; Wang R; Zhang C; He S; Sun G; Sun X
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544722
[TBL] [Abstract][Full Text] [Related]
19. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
[TBL] [Abstract][Full Text] [Related]
20. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Barron B; Mayoux E; Rector RS; Whaley-Connell A; DeMarco VG
Cardiovasc Diabetol; 2017 Jan; 16(1):9. PubMed ID: 28086951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
